Bridgewater Chapter Upcoming Events Join PCCI

 

DMK Pharma

Advancing a 3-way opioid-use disorder compound

Presenter: Joseph P. Connell

 

Monday, 7:30 pm, April 12, 2021 (Online Only)

 

About

 

DMK Pharma develops novel drugs for the medical treatment of addiction, particularly for opioid-use disorder.  As a small startup, it uses a virtual company model to get the most for its investment funds and attract talent without geographical constraints.

 

Its lead molecule, DPI-125, acts on all three opioid receptors (mu, delta and kappa), giving it unique characteristics. Initially, DMK had aimed to create a potent analgesic for a Phase I study, the value proposition being that:  mu agonism confers potent analgesic effect, delta agonism reduces respiratory depression, and kappa agonism reduces abuse liability.  These attributes have shown results in rodents and non-human primates, and also in humans through a predecessor compound with a similar receptor activation profile.

 

However, given the catastrophic opioid crisis, made worse by Covid-19, DMK decided to advance this molecule as a “Medical-Assisted Treatment for Opioid Use Disorder”. 

 

DMK’s patent portfolio comprises composition of matter and use patents issued in the US, Europe, Canada and China. DMK is also pursuing a use patent internationally for treating addiction.

 

To date, the company has been funded by founder capital and generous grants from the NIH and CSIT. The plan is to continue to apply for grants, but DMK needs to move to equity financing now, as it needs to raise approximately $10M to be able to carry out human studies to demonstrate lack of respiratory depression and abuse liability.

 

 

3 Major Issues

 

  1. As DMK Pharma has no capital, how can it best attract leadership through equity compensation prior to financing?
  2. Should DMK first try to raise around $5M to perform a human study to show safety with regards to respiratory depression, then go for additional funding?  Or should it try to get $10M initially?
  3. Where is it most likely to get funding for this project?
    • High net-worth individuals?
    • Family offices?
    • Angels, VCs, or investment bankers?

 

 

Program:

 

7:00 - "Meet and Greet" on Zoom webcast; talk with other members

7:30 - Eboo Versi, MD, PhD, Chairman & Founder of the Versi Group, owner of DMK Pharma, will deliver "Elevator" Pitch to the Group

8:00 - Panelists' comments, followed by audience Q&A Panelists: Sharon Ross, Joe Cirino and Mike Silvon Moderator: Bob Michel

 

 

 

 

Reservation is FREE
for this meeting

 

 

 

Available Media

Please note: All information obtained here is the property of those presenting and should not be copied or duplicated without written consent.

 

Slides

None available at this time

Audio

None available at this time

Video

None available at this time

Webcast

None available at this time

Contact Info:

 

 

Our Sponsors

KEH Insurance Agency
New Jersey Innovation Institute Science CenterWhite and Williams

 

<Top of the page>

 

 

 

 

Questions or Coments?

Contact: Peter van der Kam,

peter@rxpcci.com | (610) 296-8086

 

 

 

Good Company! Good Drink! Good Food! Good Program! Good Fun!

 

Site Navigation

HOME  |  ABOUT PCCI  |   DIRECTIONS  |   BRIDGEWATER DIRECTIONS  |   JOIN US  |   BOARD MEMBERS  |   AFFILIATES  |  NEXT MEETING  |  ARCHIVES

PROFILES CALENDAR OF EVENTS  |  BRIDGEWATER CHAPTER  |  FEEDBACK / COMMENTS  |   CONTACT US

Pharmaceutical Consulting Consortium International, Inc.,

info@rxpcci.com or (610) 296-8086

Meetings Held at Embassy Suites - Valley Forge

888 Chesterbrook Blvd, Chesterbrook, Pennsylvania 19087

All content on this website is copyrighted and should not be reproduced without the consent of PCCI.

© Copyright 2016-2018

 

 

Tat Communication Inc